Formulation and &lt;i&gt;In vitro/In vivo&lt;/i&gt; Evaluation of Sustained Release Diltiazem Matrix Tablets

Baviskar, Dheeraj T.; Sharma, Rajesh; Jain, Dinesh

doi:10.4314/tjpr.v12i5.3

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo study design [14] The rabbits were randomly divided into two groups each group contains six animals. The group A was received prepared Nelfinavir matrix tablets (625 mg), marketed product (625 mg) was administered group B with equivalent dose of animal body weight.…”

Section: In Vivo Bioavailability Studies Of Nelfinavir Animal Preparationmentioning

confidence: 99%

Development and in Vivo Evaluation of Nelfinavir Extended Release Trilayer Matrix Tablets in the Management of Aids

Nirmala

Gorle

2018

Int. J. Pharm. Sci. Drug Res.

View full text Add to dashboard Cite

The purpose of this investigation was to design and develop trilayer matrix tablets of Nelfinavir prepared by direct compression method and consisted of middle active layer with different grades of hydroxypropyl methylcellulose (HPMC), PVK K 30 and MCC. Barrier layers are prepared with Polyox WSR 303, Xanthan gum, microcrystalline cellulose and magnesium stearate. Based on the evaluation parameters, drug dissolution profile and release drug kinetics DF8 was found to be optimized formulation. The developed drug delivery system provided prolonged drug release rates over a period of 24 h. The release profile of the optimized formulation (DF8) was described by the Zero-order and best fitted to Higuchi model. From in vivo bioavailability studies the extended release of Nelfinavir from trilayer matrix tablets also provides for higher plasma drug content and improved bioavailability. The results indicate that the approach used could lead to a successful development of low biological half life Nelfinavir with controlled drug release in the effective management of AIDS.

show abstract

Section: In Vivo Bioavailability Studies Of Nelfinavir Animal Preparationmentioning

confidence: 99%

Development and in Vivo Evaluation of Nelfinavir Extended Release Trilayer Matrix Tablets in the Management of Aids

Nirmala

Gorle

2018

Int. J. Pharm. Sci. Drug Res.

View full text Add to dashboard Cite

show abstract

Formulation and <i>In vitro/In vivo</i> Evaluation of Sustained Release Diltiazem Matrix Tablets

Abstract: Purpose: To develop and optimise sustained release (SR) matrix tablets of diltiazem hydrochloride (DHL

Cited by 1 publication

References 9 publications

Development and in Vivo Evaluation of Nelfinavir Extended Release Trilayer Matrix Tablets in the Management of Aids

Development and in Vivo Evaluation of Nelfinavir Extended Release Trilayer Matrix Tablets in the Management of Aids

Contact Info

Product

Resources

About